Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

Inclusion Criteria:

   - Moderate to severe peanut and/or egg and/or milk and/or tree nut and/or seed allergic
   subjects between the ages of 4 to 55 years old.

   - Sensitivity to food allergen will be documented by a positive skin prick test result
   or allergen-specific ImmunoCAP IgE level, with 7 kU/L as a lower limit of eligibility.

Exclusion Criteria:

   - No absolute contraindications are known. However, the risk of serious systemic
   anaphylactic reactions to food allergens suggests a number of preexisting conditions
   that should be considered relative contraindications. Among those conditions are acute
   infections, autoimmune disease, severe cardiac disease, and treatment with
   beta-adrenergic antagonistic drugs (beta-blockers).

   - Subjects with a total IgE at screening of >2,000 kU/L

   - Previous reaction to omalizumab

   - Subjects having a history of severe anaphylaxis to food allergens that will be
   desensitized in this study requiring intubation or admission to an ICU, frequent
   allergic or non-allergic urticaria, or history consistent with poorly controlled
   persistent asthma.